Skip to main content

Table 1 Clinical characteristics of study population and inter-group difference significance levels (Mann–Whitney)

From: The influence of insulin resistance on cerebrospinal fluid and plasma biomarkers of Alzheimer’s pathology

 

Insulin non-resistant (n = 30)

Insulin resistant (n = 28)

Significance (p value)

Age (years)

62 ± 5

(55–69)

63 ± 4

(55–70)

0.33

MMSE, total score

29 ± 1

(25–30)

29 ± 1

(25–30)

0.44

BMI (kg/m2)

28.9 ± 1.8

(27.1–35.2)

30.1 ± 2.3

(27.1–36.0)

0.02*

APOE genotype (count, % ε4+)

13

43.3%

10

35.7%

0.56

Matsuda

9.1 ± 3.1

(6.4–17.2)

2.1 ± 0.3

(1.5–2.5)

0.00*

P-glucose (mmol/l)

5.7 ± 0.4

(4.8–6.7)

6.0 ± 0.6

(5.1–7.4)

0.12

P-insulin (mU/l), LIAISON

7.7 ± 3.8

(1.5–19.5)

19.6 ± 8.1

(8.0–43.2)

0.00*

P-insulin (mU/l), ELISA

5.4 ± 2.5

(1.4–12.3)

13.9 ± 6.3

(5.9–31.6)

0.00*

CSF insulin (mU/l), ELISA

0.15 ± 0.12

(0.10–0.64)

0.22 ± 0.15

(0.1–0.7)

0.00*

Aβ-42 (pg/ml), Fujirebio

856 ± 195

(530–1256)

888 ± 204

(531–1313)

0.59

T-tau (pg/ml), Fujirebio

256 ± 122

(107–670)

283 ± 110

(144–694)

0.16

P-tau (pg/ml), Fujirebio

44 ± 18

(20–105)

52 ± 28

(25–183)

0.10

CSF Aβ/tau

3.75 ± 1.0

(0.87-6.12)

3.38 ± 0.9

(1.31-5.04)

0.13

  1. Data presented as mean ± SD (minimum–maximum) or as count (percentage) for the categorical variable (APOE ε4 status)
  2. MMSE Mini-Mental State Examination, BMI body mass index, APOE apolipoprotein E, ELISA enzyme-linked immunosorbent assay, CSF cerebrospinal fluid, amyloid beta, T-tau total tau, P-tau tau phosphorylated at the Thr181 epitope
  3. *Significant at p < 0.05